Genomics-based Approaches to Drug Target Validation
Greatest growth will occur in protein microarrays, with an average annual growth rate (AAGR) of nearly 48%.
Proteomics will see growth from $1.9 billion in 2002 to $4 billion in 2007.
Bioinformatics should have an average annual growth of 14.7%.
High-throughput screening will see a 14.1% AAGR through 2007.
Drug target validation has become the critical step in maintaining profitability for pharmaceutical companies. In 2003, to replenish product pipelines, drug developers must accelerate identification and validation of potential new products. Facilitating this, genomics technologies allow companies to minimize product failures in trials and more rapidly move candidates through the development process.
In just a few years, the field of genomics has produced a vast array of technologies and products that rapidly have generated oceans of information on human genetics, disease and means of identifying “druggable” disease targets. The challenge for the next few years will be to quickly, efficiently and cost-effectively identify the most promising drug candidates from the constantly increasing plethora of possibilities.
This timely BCC report discusses the three main elements of efficiently zeroing in on viable drug candidates: target screening, target identification and target validation, with an emphasis on target validation. It provides a comprehensive analysis of the current markets for genomics-based products, services and applications as well as the potential for technologies in development. In particular, analysis is provided of the leading technologies and products in the arena of drug target validation with in-depth assessments of the companies marketing and developing these services and products.
There also is a detailed discussion of the ongoing transition of a number of genomics companies from providers of services or products into full-scale drug manufacturers and marketers. Also explored is the critical role of patents in determining leverage among genomics companies. Forecasts and trends are gleaned from industry sources as well as from considered assessments of available and emerging technologies. Forecasts for leading technologies and services used in genomics-based drug target validation are provided for 2001 and projected for 2002 and 2007.
SCOPE OF STUDY
This report provides coverage of:
- Why genomics-based drug target validation is so critical
- Definitions of the components used in genomics
- Drug target validation technologies and services including current status, obstacles, opportunities
- Companies, their technologies and profiles; industry structure, regulatory issues, role of patents
- Five-year market forecasts for genomicsbased products, services and applications.
The information and analysis presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries. In addition, a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations are provided as well.
Lynn Gray has been a research analyst since 1989 and with BCC since 1996. During that time, she has authored numerous reports in the biomedical field, 18 for BCC alone. BA, University of California, Riverside, 1973.
Genomics is quietly transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses either have formed partnerships with genomics firms that began to emerge in the early 1990s or have created in-house genomics divisions. As little as 2 years ago, there were only a dozen or so firms in the genomics industry. In 1999, there are estimated to be more than 200 companies worldwide.
The market for genetic data and technology is projected to be worth tens of billions of dollars within the next decade. Products provided by genomics firms include not only databases but also specialized software to search the databases. Besides databases, another genomics product is the DNA (deoxyribonucleic acid) biochip (also called the DNA microassay or DNA chip), which is able to analyze hundreds of samples simultaneously with nucleic acid probes placed on a glass wafer.